drugset / Trial / NCT05437328
GD2/CD56 Bi-specific CAR-T Cell Therapy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/CD56 bi-specific CAR-T cell therapy in patients with GD2 and/or CD56 positive cancer. Another goal of the study is to learn more about the function of the anti-GD2/CD56 bi-specific CAR-T cells and their persistency in patients.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2029-12-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bi-4SCAR GD2/CD56 T cells | Cell therapy | 1e+06 cells/kg | Intravenous |